THAR - Tharimmune Inc.

https://www.tharimmune.com

Momentum: Bearish

Recent News

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

GlobeNewswire • 1 week, 4 days ago • score: 0.00

RED BANK, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Tharimmune, Inc. ( Nasdaq: THAR ) , a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating ...

Neutral

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl - Tharimmune ( NASDAQ:THAR )

Benzinga • 1 week, 4 days ago • score: -0.01

RED BANK, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Tharimmune, Inc. THAR, a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three ...

Bullish

Tharimmune Shares Are Trading Lower Tuesday: What's Going On? - Tharimmune ( NASDAQ:THAR )

Benzinga • 2 weeks, 5 days ago • score: 0.74

Tharimmune enters a securities purchase agreement for 1,188,888 shares of common stock or equivalents at $4.50 per share. The offering is expected to close August 27, 2025, with placement agents receiving a 10% cash fee from proceeds. See the 6X seasonal strategy set to target this fall's ...

Bullish

Tharimmune ( THAR ) Stock Is Surging Monday: What's Going On? - Tharimmune ( NASDAQ:THAR )

Benzinga • 2 weeks, 6 days ago • score: 0.48

Shares of Tharimmune are surging in Monday afternoon trading. The company last week announced promising simulation results for its lead clinical asset, TH104. The market is reacting to Powell's speech. Learn how to time your next move. Details here →

Bullish

Tharimmune ( THAR ) Shares Skyrocket On Promising Opioid Countermeasure Data - Tharimmune ( NASDAQ:THAR )

Benzinga • 3 weeks, 3 days ago • score: 0.47

Shares of Tharimmune are surging Thursday afternoon. The company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →

Neutral

Tharimmune Rockets 42% After Hours - Adding To Stunning 206% Daytime Rally: What's Going On? - Tharimmune ( NASDAQ:THAR )

Benzinga • 3 weeks, 4 days ago • score: 0.07

Tharimmune Inc. THAR jumped 42.06% to $5.10 in after-hours trading on Wednesday following positive pharmacokinetic simulation results for its lead drug candidate TH104, designed to prevent respiratory depression from fentanyl exposure. Check out the current price of THAR stock here.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$9.08

52W Low

$0.95

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.59

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.32

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

53.46

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

16.96%

Institutions (25–75% balanced)

1.48%

Shares Outstanding

5,336,400

Float

3,468,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-6.06

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1730

0.2502

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025